A new children's vaccine made by GlaxoSmithKline that targets two common causes of bacterial meningitis has been approved by federal regulators.
The MenHibrix vaccine is for children 6 weeks to 18 months old. The drug combines the vaccines for meningococcal disease and Hib disease. Both diseases can cause bacterial meningitis, which is an infection of the thin lining surrounding the brain and spinal cord. It can be fatal if untreated.
The U.S. Food and Drug Administration rejected MenHibrix in 2010 and last year, but GSK has since resolved regulators' questions about the vaccine's potency.
GSK employs about 3,800 people in Resarch Triangle Park, where it has its U.S. headquarters and another 600 at a manufacturing facility in Zebulon.
The vaccines division behind MenHibrix is based in Belgium.